The company's Bellaspas Tablets were determined to no longer be covered by a current NDA. The firm was advised that it would need to apply for another NDA to continue to sell this product.
Further, the agency added that drug products containing ergotamine were marketed under NDAs approved for safety only before 1962.
Next, the drugs are available for prescription only and must have labels with adequate directions for safe use, the letter noted.
Also, FDA stated that the label must bear a warning regarding possible risks of life-threatening ischemia, including fatalities and cases of gangrene, which have resulted from concomitant use.
Also, though some ergotamine products were found to be effective for certain indications, this does not necessarily mean that the firm's products as currently formulated, manufactured, and labeled, is effective or safe, according to FDA. Lab; NDA; Doc. 14102W




Mobile Edition
Print
Get the Mag
Weekly Updates